Global Blood Therapeutics Dirección
Dirección controles de criterios 4/4
El CEO de Global Blood Therapeutics es Ted Love , nombrado en Jun 2014, tiene una permanencia de 8.33 años. compensación anual total es $8.19M, compuesta por 8.7% salario y 91.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.37% de las acciones de la empresa, por valor de $63.19M. La antigüedad media del equipo directivo y de la junta directiva es de 6.5 años y 5.8 años, respectivamente.
Información clave
Ted Love
Chief Executive Officer (CEO)
US$8.2m
Compensación total
| Porcentaje del salario del CEO | 8.7% |
| Permanencia del CEO | 8.3yrs |
| Participación del CEO | 1.4% |
| Permanencia media de la dirección | 6.5yrs |
| Promedio de permanencia en la Junta Directiva | 5.8yrs |
Actualizaciones recientes de la dirección
Recent updates
Global Blood Therapeutics expects to complete Pfizer deal in early October
Sep 30Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals
Sep 16Pfizer said to have had bidding war with Johnson & Johnson for Global Blood
Aug 24What Pfizer Is Getting Through The Acquisition Of Global Blood Therapeutics
Aug 08Global Blood Therapeutics to expand access to its sickle cell disease treatment in Brazil
Jul 14GBT begins phase 2/3 clinical trial of GBT601 to treat sickle cell disease
Jun 29Global Blood Therapeutics: Powerhouse Of The Future
Jun 21Global Blood Therapeutics (NASDAQ:GBT) Is Making Moderate Use Of Debt
Jun 07
Global Blood Therapeutics: Hitting A Growth Inflection
Apr 12Global Blood Therapeutics: Changing My Strategy After Recent Earnings
Mar 12Is Global Blood Therapeutics (NASDAQ:GBT) Using Too Much Debt?
Feb 24Global Blood Therapeutics: Revisiting A Stellar Grower
Dec 25IBI Research On Global Blood Therapeutics: Galvanized For Growth
Nov 30Despite Lacking Profits Global Blood Therapeutics (NASDAQ:GBT) Seems To Be On Top Of Its Debt
Nov 03Global Blood Therapeutics: It Might Be Time To Buy The Dip
Oct 24Global Blood Therapeutics: Attempting To Classify The Investment
Aug 07Global Blood Therapeutics (NASDAQ:GBT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jul 08Shareholders May Not Be So Generous With Global Blood Therapeutics, Inc.'s (NASDAQ:GBT) CEO Compensation And Here's Why
Jun 12Global Blood Therapeutics announces employment inducement grants
Jun 04Global Blood Therapeutics: Increasing Specialization In SCD
May 09Is Global Blood Therapeutics (NASDAQ:GBT) A Risky Investment?
Mar 18Breakeven On The Horizon For Global Blood Therapeutics, Inc. (NASDAQ:GBT)
Feb 20
Did Business Growth Power Global Blood Therapeutics' (NASDAQ:GBT) Share Price Gain of 152%?
Jan 25Have Insiders Been Buying Global Blood Therapeutics, Inc. (NASDAQ:GBT) Shares?
Dec 29Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2022 | n/a | n/a | -US$322m |
| Mar 31 2022 | n/a | n/a | -US$310m |
| Dec 31 2021 | US$8m | US$716k | -US$303m |
| Sep 30 2021 | n/a | n/a | -US$277m |
| Jun 30 2021 | n/a | n/a | -US$266m |
| Mar 31 2021 | n/a | n/a | -US$249m |
| Dec 31 2020 | US$18m | US$661k | -US$248m |
| Sep 30 2020 | n/a | n/a | -US$282m |
| Jun 30 2020 | n/a | n/a | -US$286m |
| Mar 31 2020 | n/a | n/a | -US$291m |
| Dec 31 2019 | US$10m | US$597k | -US$267m |
| Sep 30 2019 | n/a | n/a | -US$220m |
| Jun 30 2019 | n/a | n/a | -US$199m |
| Mar 31 2019 | n/a | n/a | -US$182m |
| Dec 31 2018 | US$10m | US$569k | -US$174m |
| Sep 30 2018 | n/a | n/a | -US$166m |
| Jun 30 2018 | n/a | n/a | -US$152m |
| Mar 31 2018 | n/a | n/a | -US$135m |
| Dec 31 2017 | US$8m | US$520k | -US$117m |
| Sep 30 2017 | n/a | n/a | -US$103m |
| Jun 30 2017 | n/a | n/a | -US$95m |
| Mar 31 2017 | n/a | n/a | -US$89m |
| Dec 31 2016 | US$1m | US$479k | -US$82m |
| Sep 30 2016 | n/a | n/a | -US$71m |
| Jun 30 2016 | n/a | n/a | -US$65m |
| Mar 31 2016 | n/a | n/a | -US$58m |
| Dec 31 2015 | US$2m | US$438k | -US$51m |
Compensación vs. Mercado: La compensación total ($USD8.19M) de Ted está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD6.54M).
Compensación vs. Ingresos: La compensación de Ted ha sido consistente con los resultados de la empresa en el último año.
CEO
Ted Love (63 yo)
8.3yrs
Permanencia
US$8,193,309
Compensación
Dr. Ted W. Love, M.D., serves as Independent Director at Royalty Pharma plc since July 30, 2020. He serves as Director of Seagen Inc. (formerly known as Seattle Genetics, Inc.). since August 2020. He serve...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 8.3yrs | US$8.19m | 1.37% $ 63.2m | |
| CFO & Principal Accounting Officer | 6.5yrs | US$2.76m | 0.040% $ 1.8m | |
| Chief Business & Strategy Officer | 7.5yrs | US$2.73m | 0.37% $ 17.2m | |
| Chief Commercial Officer | 4.6yrs | US$2.75m | 0.084% $ 3.9m | |
| Executive VP and Head of Research & Development | 1.4yrs | US$2.98m | 0.0089% $ 409.5k | |
| Founder & Advisor | 11.8yrs | sin datos | sin datos | |
| Founder & Advisor | 11.8yrs | sin datos | sin datos | |
| Founder & Advisor | 11.8yrs | sin datos | sin datos | |
| Executive Vice President of Operations | 2.5yrs | sin datos | 0.062% $ 2.9m | |
| Senior Director of Corporate Communications & Investor Relations | no data | sin datos | sin datos | |
| Chief Legal Officer & Secretary | 6yrs | US$5.93m | 0.064% $ 3.0m | |
| Senior VP & Head of Corporate Communications | 3.8yrs | sin datos | sin datos |
6.5yrs
Permanencia media
60yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de GBT es experimentado (6.5 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 9.1yrs | US$8.19m | 1.37% $ 63.2m | |
| Lead Independent Director | 7.5yrs | US$348.28k | 0.056% $ 2.6m | |
| Independent Director | 4.8yrs | US$320.78k | 0.017% $ 783.3k | |
| Independent Director | 2.4yrs | US$313.28k | 0.013% $ 618.8k | |
| Independent Director | 6.7yrs | US$318.28k | 0.039% $ 1.8m | |
| Independent Director | 7.1yrs | US$310.78k | 0.013% $ 623.9k | |
| Independent Director | 6.8yrs | US$333.28k | 0.0098% $ 454.8k | |
| Independent Director | 3.8yrs | US$316.36k | 0.0080% $ 368.3k | |
| Advisor & Director Emeritus | less than a year | US$308.28k | 0.058% $ 2.7m | |
| Independent Director | 1.6yrs | US$735.61k | 0.0049% $ 226.5k |
5.8yrs
Permanencia media
66yo
Promedio de edad
Junta con experiencia: La junta directiva de GBT se considera experimentada (5.8 años de antigüedad promedio).